Clearwater, FL - (NewMediaWire) - October 21, 2024 - REMSleep Holdings, Inc. (OTCQB: RMSL) announces that it has been granted a Utility Patent by the United States Patent and Trademark office.

(12) United StatesPatent (10) Patent No.: US 12,115,315B2 Wood (45) Date of Patent:Oct. 15, 2024

REMSleep has received delivery of silicone material for production of inventory of the new 510(K) cleared Deltawave nasal pillow interface mask.. Remsleep is waiting on molder to begin production.  We are expecting Deltawave to be available for market soon.  We have major distributors waiting to receive samples and expect to have Deltawave available for direct to consumer as soon as we receive our first inventory.

The Deltawave journey has been long and brutal.  We are hardly unaware of the agony.  However, we know it can’t possibly be much longer before Deltawave is available for sleep apnea sufferers, which has been the goal.

About REMSleep Holdings, Inc.

REMSleep Holdings, Inc. is a medical device manufacturer dedicated to forever changing the level of treatment provided to obstructive sleep apnea patients. Our focus is primarily designing and manufacturing devices and products for the treatment of sleep apnea and other respiratory conditions. With over 30 years of collective experience in CPAP therapy, the REMSleep team has extensive knowledge and understanding of CPAP and the challenges of patient compliance. We diligently strive for our products to make a difference and improve the condition of those suffering from sleep apnea.

Forward-looking Statements

This press release may contain forward-looking statements regarding the Company. All statements, other than statements of historical fact included herein, are "forward-looking statements" including statements regarding the Company’s future prospects and risks in investing in Company’s common stock. These statements are based upon the Company's current expectations and speak only as of the date hereof. Financial performance in one period does not necessarily mean continued or better performance in the future. The Company's actual results in any endeavor may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, which factors or uncertainties may be beyond our ability to foresee or control. Other risk factors include the status of the Company's common stock as a "penny stock" and those risk factors stated in reports filed with the U.S. Securities and Exchange Commission or SEC on its EDGAR website (URL:www.sec.gov)

Contact:

REMSleep Holdings, Inc.

14175 ICOT Blvd

Suite 300

Clearwater, FL 33760

Email: twood@remsleep.com

Phone: 912-590-2001

This press release is distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is REMSleep Receives issuance of Patent by the United States Patent and Trademark Office.